Study to test a kidney cancer prediction model
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with renal cell carcinoma (a type of kidney cancer) before and during your surgery.
- You had surgery to remove the whole kidney (radical nephrectomy) or surgery to remove just the tumor (nephron-sparing surgery).
- You do not have a history of other cancers.
- Your cancer did not come back before your first follow-up after surgery.
- You did not stop any adjuvant treatment within the first two courses due to severe side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses information from scans and surgery findings to build a prediction model for people with kidney cancer that has grown into a major vein (the IVC). It aims to help doctors better estimate outcomes and guide care after surgery.
This study uses a computer model to analyze your CT scans and predict how long you might stay cancer-free after surgery. It aims to help doctors personalize follow-up care for clear cell kidney cancer.
This trial is for people with renal (kidney) cancer who have already had surgery. The study is testing whether a computer method can use medical information from you to improve kidney-cancer detection.
This study follows people with kidney cancer who are scheduled for surgery to remove their tumor. It aims to learn more about the disease and how it behaves over time.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
Hear when a new Renal Cell Carcinoma (Kidney Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.